BioPharmaPT
โ† All reports

Ipsen S.A. โ€” Cabometyx EMA EPAR variation assessment report (EMEA/H/C/004163, 2016)

Ipsen S.A. ยท 2016 ยท EMA EPAR variation assessment report ยท company profile โ†’

Report summary

This report summarizes the CHMP's assessment of Ipsen Pharma's Type II variation for CABOMETYX (cabozantinib) to include progressive extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors. The application is based on the CABINET Phase III trial, which compared cabozantinib to placebo in advanced epNET and pNET patients after prior therapy. The study demonstrated significant improvements in progression-free survival for cabozantinib in both cohorts (HR 0.38 for epNET, 0.23 for pNET). While overall survival data were immature and confounded by crossover, the safety profile was consistent with previous findings, with a higher incidence of adverse events in the cabozantinib arm. The report also reviewed non-clinical aspects and pharmacokinetic data.

Key findings โ€” cited to the page

Grade 3-4 AEs (all causality) for cabozantinib in epNET67 %CABINET ยท p.145
Grade 3-4 AEs (all causality) for placebo in epNET39 %CABINET ยท p.145
Grade 3/4 AEs in cabozantinib arm69 %CABINET ยท p.143
Grade 3/4 AEs in placebo arm41 %CABINET ยท p.143
Worst Grade 3 or 4 AE (cabozantinib, epNET)89 CABINET ยท p.90
Worst Grade 5 AE (cabozantinib, epNET)9 CABINET ยท p.90
Worst Grade 5 AE (placebo, epNET)5 CABINET ยท p.90
Worst Grade 3 or 4 AE (placebo, epNET)26 CABINET ยท p.90
Worst Grade 3 or 4 AE (cabozantinib, pNET)46 CABINET ยท p.90
Grade 3-4 AEs (drug-related) for placebo in pNET23 %CABINET ยท p.145
Worst Grade 3 or 4 AE (placebo, pNET)14 CABINET ยท p.90
Grade 3-4 AEs (drug-related) for cabozantinib in epNET59 %CABINET ยท p.145

Source: Ipsen S.A. โ†— ยท License: EMA - reuse permitted with acknowledgement. Summary and findings are extracted from the published document; every figure cites its page. Informational only โ€” not investment advice. Explore the Oncology library โ†’

Ipsen S.A. โ€” Cabometyx EMA EPAR variation assessment report (EMEA/H/C/004163, 2016) โ€” Summary & Key Findings | BioPharmaPT